Currently, breast cancer patients receive different kinds of therapy, with monoclonal antibodies against human epidermal growth factor receptor 2 (HER2) and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors being the most commonly used targeted agents (9, 10). This evidence concerns the gene ERBB2 and breast carcinoma.